Deutsch English Français

Contact

EP2517557

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP2517557

EP2517557 - Animal models and therapeutic molecules [Right-click to bookmark this link]
Status	Patent maintained as amended Status updated on 30.06.2023 Database last updated on 23.04.2024
Most recent event Tooltip	30.06.2023	Patent maintained (B2 publication)	published on 02.08.2023 [2023/31]
Applicant(s)	For all designated states Kymab Limited The Bennet Building (B930) Babraham Research Campus Cambridge CB22 3AT / GB
	[2023/31]
Former [2015/22]	For all designated states Kymab Limited The Bennet Building (B930) Babraham Research Campus Cambridge CB22 3AT / GB
Former [2012/44]	For all designated states Kymab Limited Meditrina (B260) Babraham Research Campus Cambridge, Cambridgeshire CB22 3AT / GB
Inventor(s)	01 / Bradley, Allan c/o Kymab Limited The Bennet Building (930) Babraham Research Campus Cambridge CB22 3AT / GB
	02 / Lee, E-Chiang c/o Kymab Limited The Bennet Building (930) Babraham Research Campus Cambridge CB22 3AT / GB
	03 / Liang, Qi c/o Kymab Limited The Bennet Building Babraham Research Campus Cambridge CB22 3AT / GB
	04 / Wang, Wei c/o Kymab Limited The Bennet Building Babraham Research Campus Cambridge CB22 3AT / GB
	[2016/15]
Former [2014/12]	01 / Bradley, Allan c/o Kymab Limited Meditrina (B260) Babraham Research Campus Cambridge, Cambridgeshire CB22 3AT / GB
	02 / Lee, E-Chiang c/o Kymab Limited Meditrina (B260) Babraham Research Campus Cambridge, Cambridgeshire CB22 3AT / GB
	03 / Liang, Qi c/o Kymab Limited Meditrina (B260) Babraham Research Campus Cambridge, Cambridgeshire CB22 3AT / GB
	04 / Wang, Wei c/o Kymab Limited Meditrina (B260) Babraham Research Campus Cambridge, Cambridgeshire CB22 3AT / GB
Former [2012/44]	01 / Bradley, Allan c/o Genome Research Limited Gibbs Building, 215 Euston Road London, Greater London NW1 2BE / GB
	02 / Lee, E-Chiang c/o Genome Research Limited Gibbs Building, 215 Euston Road London, Greater London NW1 2BE / GB
	03 / Liang, Qi c/o Genome Research Limited Gibbs Building, 215 Euston Road London, Greater London NW1 2BE / GB
	04 / Wang, Wei c/o Genome Research Limited Gibbs Building, 215 Euston Road London, Greater London NW1 2BE / GB
Representative(s)	CMS Cameron McKenna Nabarro Olswang LLP Cannon Place 78 Cannon Street London EC4N 6AF / GB
	[2023/31]
Former [2012/44]	Stephen, Robert John Olswang LLP 90 High Holborn London WC1V 6XX / GB
Application number, filing date	12171793.8	07.07.2010
	[2012/44]
Priority number, date	GB20090011846	08.07.2009 Original published format: GB 0911846
	US20090223960P	08.07.2009 Original published format: US 223960 P
	GB20090013102	28.07.2009 Original published format: GB 0913102
	US20100355666P	17.06.2010 Original published format: US 355666 P
	[2012/44]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	EP2517557
	Date:	31.10.2012
	Language:	EN
	[2012/44]
	Type:	A3 Search report
	No.:	EP2517557
	Date:	24.07.2013
	Language:	EN
	[2013/30]
	Type:	B1 Patent specification
	No.:	EP2517557
	Date:	13.04.2016
	Language:	EN
	[2016/15]
	Type:	B2 New European patent specification
	No.:	EP2517557
	Date:	02.08.2023
	Language:	EN
	[2023/31]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	21.06.2013
Classification	IPC:	A01K67/027, C07K16/00, C07K16/46, C12N15/85	[2012/44]
	CPC:	A01K67/0278 (EP,KR,US); A01K67/027 (KR); A01K67/0271 (US); A01K67/0275 (US); A01K67/0276 (US); A61K39/107 (US); (+) A61K39/35 (US); A61P37/02 (EP); C07K16/00 (EP,KR,US); C07K16/1203 (US); C07K16/1239 (US); C07K16/18 (US); C07K16/462 (EP,KR,US); C12N15/8509 (EP,KR,US); A01K2207/15 (EP,KR,US); A01K2217/05 (US); A01K2217/052 (EP,KR,US); A01K2217/072 (US); A01K2217/075 (US); A01K2217/15 (US); A01K2227/105 (EP,KR,US); A01K2267/01 (EP,US); A61K2039/505 (US); C07K2317/14 (US); C07K2317/21 (US); C07K2317/24 (EP,KR,US); C07K2317/51 (US); C07K2317/515 (US); C07K2317/52 (US); C07K2317/56 (US); C07K2317/565 (US); C07K2317/567 (US); C07K2317/76 (US); C07K2317/92 (US); C12N2015/8518 (US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2016/15]
Former [2012/44]	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR
Title	German:	Tiermodelle und therapeutische Moleküle	[2012/44]
	English:	Animal models and therapeutic molecules	[2012/44]
	French:	Modèles animaux et molécules thérapeutiques	[2012/44]
Examination procedure	06.09.2013	Amendment by applicant (claims and/or description)
	17.09.2013	Examination requested [2013/43]
	27.02.2014	Despatch of a communication from the examining division (Time limit: M04)
	19.05.2014	Reply to a communication from the examining division
	16.06.2014	Despatch of a communication from the examining division (Time limit: M06)
	25.06.2014	Observations by third parties
	05.01.2015	Reply to a communication from the examining division
	17.03.2015	Observations by third parties
	22.04.2015	Despatch of a communication from the examining division (Time limit: M02)
	23.04.2015	Reply to a communication from the examining division
	22.05.2015	Observations by third parties
	11.09.2015	Communication of intention to grant the patent
	11.01.2016	Fee for grant paid
	11.01.2016	Fee for publishing/printing paid
	24.02.2016	Information about intention to grant a patent
	24.02.2016	Receipt of the translation of the claim(s)
Parent application(s) Tooltip	EP10734546.4 / EP2421357
Divisional application(s)	EP14170196.1 / EP2798950
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20100734546) is 12.03.2012
Opposition(s)	Opponent(s)	01 11.01.2017 31.10.2022 WITHDRAWN Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown NY 10591 / US Opponent's representative J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB
		[2022/49]
	Former [2017/32]
	Opponent(s)	01 11.01.2017 20.01.2017 ADMISSIBLE Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown NY 10591 / US Opponent's representative J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
	Former [2017/07]
	Opponent(s)	01 11.01.2017 Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown NY 10591 / US Opponent's representative Bentham, Andrew J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
	17.02.2017	Invitation to proprietor to file observations on the notice of opposition
	23.06.2017	Reply of patent proprietor to notice(s) of opposition
	17.07.2018	Date of oral proceedings
	08.08.2018	Despatch of minutes of oral proceedings
	10.05.2022	Despatch of a communication from the opposition division (Time limit: M04)
	29.06.2022	Reply to a communication from the opposition division
	20.10.2022	Despatch of a communication from the opposition division (Time limit: M04)
	29.11.2022	Despatch of interlocutory decision in opposition
	09.12.2022	Legal effect of interlocutory decision in opposition
	16.03.2023	Despatch of communication that the patent will be maintained as amended
	26.06.2023	Fee for printing new specification paid
Appeal following opposition	26.07.2018	Appeal received No. T1990/18
	05.11.2021	Result of appeal procedure: maintenance in amended form
	26.04.2022	Despatch of the decision of the Board of Appeal
	05.11.2021	Date of oral proceedings
Fees paid	Renewal fee
	13.06.2012	Renewal fee patent year 03
	29.07.2013	Renewal fee patent year 04
	28.07.2014	Renewal fee patent year 05
	27.07.2015	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	07.07.2010
	AL	13.04.2016
	AT	13.04.2016
	BE	13.04.2016
	BG	13.04.2016
	CY	13.04.2016
	CZ	13.04.2016
	EE	13.04.2016
	ES	13.04.2016
	FI	13.04.2016
	HR	13.04.2016
	IS	13.04.2016
	IT	13.04.2016
	LT	13.04.2016
	LV	13.04.2016
	MC	13.04.2016
	MK	13.04.2016
	PL	13.04.2016
	RO	13.04.2016
	SE	13.04.2016
	SI	13.04.2016
	SK	13.04.2016
	SM	13.04.2016
	TR	13.04.2016
	LU	07.07.2016
	NO	13.07.2016
	GR	14.07.2016
	CH	31.07.2016
	LI	31.07.2016
	MT	31.07.2016
	PT	16.08.2016
	[2018/46]
Former [2018/38]	HU	07.07.2010
	AT	13.04.2016
	BE	13.04.2016
	BG	13.04.2016
	CY	13.04.2016
	CZ	13.04.2016
	EE	13.04.2016
	ES	13.04.2016
	FI	13.04.2016
	HR	13.04.2016
	IS	13.04.2016
	IT	13.04.2016
	LT	13.04.2016
	LV	13.04.2016
	MC	13.04.2016
	MK	13.04.2016
	PL	13.04.2016
	RO	13.04.2016
	SE	13.04.2016
	SI	13.04.2016
	SK	13.04.2016
	SM	13.04.2016
	TR	13.04.2016
	LU	07.07.2016
	NO	13.07.2016
	GR	14.07.2016
	CH	31.07.2016
	LI	31.07.2016
	MT	31.07.2016
	PT	16.08.2016
Former [2018/31]	HU	07.07.2010
	AT	13.04.2016
	BE	13.04.2016
	CY	13.04.2016
	CZ	13.04.2016
	EE	13.04.2016
	ES	13.04.2016
	FI	13.04.2016
	HR	13.04.2016
	IS	13.04.2016
	IT	13.04.2016
	LT	13.04.2016
	LV	13.04.2016
	MC	13.04.2016
	MK	13.04.2016
	PL	13.04.2016
	RO	13.04.2016
	SE	13.04.2016
	SI	13.04.2016
	SK	13.04.2016
	SM	13.04.2016
	TR	13.04.2016
	LU	07.07.2016
	NO	13.07.2016
	GR	14.07.2016
	CH	31.07.2016
	LI	31.07.2016
	MT	31.07.2016
	PT	16.08.2016
Former [2018/29]	HU	07.07.2010
	AT	13.04.2016
	BE	13.04.2016
	CY	13.04.2016
	CZ	13.04.2016
	EE	13.04.2016
	ES	13.04.2016
	FI	13.04.2016
	HR	13.04.2016
	IT	13.04.2016
	LT	13.04.2016
	LV	13.04.2016
	MC	13.04.2016
	MK	13.04.2016
	PL	13.04.2016
	RO	13.04.2016
	SE	13.04.2016
	SI	13.04.2016
	SK	13.04.2016
	SM	13.04.2016
	TR	13.04.2016
	LU	07.07.2016
	NO	13.07.2016
	GR	14.07.2016
	CH	31.07.2016
	LI	31.07.2016
	PT	16.08.2016
Former [2018/28]	HU	07.07.2010
	AT	13.04.2016
	BE	13.04.2016
	CY	13.04.2016
	CZ	13.04.2016
	EE	13.04.2016
	ES	13.04.2016
	FI	13.04.2016
	HR	13.04.2016
	IT	13.04.2016
	LT	13.04.2016
	LV	13.04.2016
	MC	13.04.2016
	MK	13.04.2016
	PL	13.04.2016
	RO	13.04.2016
	SE	13.04.2016
	SI	13.04.2016
	SK	13.04.2016
	SM	13.04.2016
	LU	07.07.2016
	NO	13.07.2016
	GR	14.07.2016
	CH	31.07.2016
	LI	31.07.2016
	PT	16.08.2016
Former [2017/37]	AT	13.04.2016
	BE	13.04.2016
	CZ	13.04.2016
	EE	13.04.2016
	ES	13.04.2016
	FI	13.04.2016
	HR	13.04.2016
	IT	13.04.2016
	LT	13.04.2016
	LV	13.04.2016
	MC	13.04.2016
	PL	13.04.2016
	RO	13.04.2016
	SE	13.04.2016
	SI	13.04.2016
	SK	13.04.2016
	SM	13.04.2016
	LU	07.07.2016
	NO	13.07.2016
	GR	14.07.2016
	CH	31.07.2016
	LI	31.07.2016
	PT	16.08.2016
Former [2017/24]	AT	13.04.2016
	BE	13.04.2016
	CZ	13.04.2016
	EE	13.04.2016
	ES	13.04.2016
	FI	13.04.2016
	HR	13.04.2016
	IT	13.04.2016
	LT	13.04.2016
	LV	13.04.2016
	MC	13.04.2016
	PL	13.04.2016
	RO	13.04.2016
	SE	13.04.2016
	SI	13.04.2016
	SK	13.04.2016
	SM	13.04.2016
	NO	13.07.2016
	GR	14.07.2016
	CH	31.07.2016
	LI	31.07.2016
	PT	16.08.2016
Former [2017/22]	AT	13.04.2016
	BE	13.04.2016
	CZ	13.04.2016
	EE	13.04.2016
	ES	13.04.2016
	FI	13.04.2016
	HR	13.04.2016
	IT	13.04.2016
	LT	13.04.2016
	LV	13.04.2016
	MC	13.04.2016
	PL	13.04.2016
	RO	13.04.2016
	SE	13.04.2016
	SK	13.04.2016
	SM	13.04.2016
	NO	13.07.2016
	GR	14.07.2016
	CH	31.07.2016
	LI	31.07.2016
	PT	16.08.2016
Former [2017/11]	AT	13.04.2016
	BE	13.04.2016
	CZ	13.04.2016
	EE	13.04.2016
	ES	13.04.2016
	FI	13.04.2016
	HR	13.04.2016
	IT	13.04.2016
	LT	13.04.2016
	LV	13.04.2016
	PL	13.04.2016
	RO	13.04.2016
	SE	13.04.2016
	SK	13.04.2016
	SM	13.04.2016
	NO	13.07.2016
	GR	14.07.2016
	PT	16.08.2016
Former [2017/10]	AT	13.04.2016
	BE	13.04.2016
	CZ	13.04.2016
	EE	13.04.2016
	ES	13.04.2016
	FI	13.04.2016
	HR	13.04.2016
	IT	13.04.2016
	LT	13.04.2016
	LV	13.04.2016
	PL	13.04.2016
	RO	13.04.2016
	SE	13.04.2016
	SK	13.04.2016
	NO	13.07.2016
	GR	14.07.2016
	PT	16.08.2016
Former [2017/09]	AT	13.04.2016
	BE	13.04.2016
	CZ	13.04.2016
	EE	13.04.2016
	ES	13.04.2016
	FI	13.04.2016
	HR	13.04.2016
	IT	13.04.2016
	LT	13.04.2016
	LV	13.04.2016
	PL	13.04.2016
	RO	13.04.2016
	SE	13.04.2016
	NO	13.07.2016
	GR	14.07.2016
	PT	16.08.2016
Former [2017/03]	AT	13.04.2016
	BE	13.04.2016
	ES	13.04.2016
	FI	13.04.2016
	HR	13.04.2016
	IT	13.04.2016
	LT	13.04.2016
	LV	13.04.2016
	PL	13.04.2016
	SE	13.04.2016
	NO	13.07.2016
	GR	14.07.2016
	PT	16.08.2016
Former [2016/52]	AT	13.04.2016
	ES	13.04.2016
	FI	13.04.2016
	HR	13.04.2016
	LT	13.04.2016
	LV	13.04.2016
	PL	13.04.2016
	SE	13.04.2016
	NO	13.07.2016
	GR	14.07.2016
	PT	16.08.2016
Former [2016/51]	AT	13.04.2016
	ES	13.04.2016
	FI	13.04.2016
	HR	13.04.2016
	LT	13.04.2016
	LV	13.04.2016
	PL	13.04.2016
	NO	13.07.2016
	GR	14.07.2016
	PT	16.08.2016
Former [2016/50]	AT	13.04.2016
	ES	13.04.2016
	FI	13.04.2016
	HR	13.04.2016
	LT	13.04.2016
	LV	13.04.2016
	PL	13.04.2016
	NO	13.07.2016
Former [2016/49]	FI	13.04.2016
	LT	13.04.2016
	PL	13.04.2016
	NO	13.07.2016
Former [2016/46]	LT	13.04.2016
	NO	13.07.2016
Documents cited:	Search	[XY]WO02066630 (REGENERON PHARMA [US], et al) [X] 1,3-6,16-19,22-26 * page 9, line 15 - page 14, line 23; example 3; claims 1-50 * [Y] 2,7-13;
		[A]WO03047336 (ABGENIX INC [US], et al) [A] 1-27* claims 1-81 *;
		[XY]US2006015957 (LONBERG NILS [US], et al) [X] 14,17-20,22-27 * paragraph [0249] - paragraph [0368]; claims 17-32 * [Y] 2,7,11-13;
		[Y]WO2009080254 (HOFFMANN LA ROCHE [CH], et al) [Y] 8-10 * page 10 - page 11; figure 4 *;
		[E]WO2011163314 (REGENERON PHARMA [US], et al) [E] 15 * page 11 - page 12 *
	by applicant	US5859307
		WO9929837
		WO0104288
		WO2007117410
		WO2010039900
		- ADAMS DJ; QUAIL MA; COX T; VAN DER WEYDEN L; GORICK BD; SU Q; CHAN WI; DAVIES R; BONFIELD JK; LAW F, "A genome-wide, end-sequenced 129Sv BAC library resource for targeting vector construction", GENOMICS, (20051027), vol. 86, no. 6, doi:doi:10.1016/j.ygeno.2005.08.003, pages 753 - 8, XP005265840 DOI: http://dx.doi.org/10.1016/j.ygeno.2005.08.003
		- OSOEGAWA K ET AL., GENOME RESEARCH, (2001), vol. 11, pages 483 - 496
		- PASQUALINI; ARAP, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (2004), vol. 101, pages 257 - 259
		- BARRETT, M.T.; SCHEFFER, A.; BEN-DOR, A.; SAMPAS, N.; LIPSON, D.; KINCAID, R.; TSANG, P.; CURRY, B.; BAIRD, K.; MELTZER, P.S. ET A, "Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (2004), vol. 101, doi:doi:10.1073/pnas.0407979101, pages 17765 - 17770, XP002630628 DOI: http://dx.doi.org/10.1073/pnas.0407979101
		- RAMIREZ-SOLIS R; LIU P; BRADLEY A, "Chromosome engineering in mice", NATURE, (1995), vol. 378, no. 6558, doi:doi:10.1038/378720a0, pages 720 - 4, XP001026456 DOI: http://dx.doi.org/10.1038/378720a0
		- PROSSER, H.M.; RZADZINSKA, A.K.; STEEL, K.P.; BRADLEY, A., "Mosaic complementation demonstrates a regulatory role for myosin Vila in actin dynamics of stereocilia", MOLECULAR AND CELLULAR BIOLOGY, (2008), vol. 28, pages 1702 - 1712
		- RAMIREZ-SOLIS, R.; DAVIS, A.C.; BRADLEY, A., "Gene targeting in embryonic stem cells", METHODS IN ENZYMOLOGY, (1993), vol. 225, doi:doi:10.1016/0076-6879(93)25054-6, pages 855 - 878, XP000918540 DOI: http://dx.doi.org/10.1016/0076-6879(93)25054-6
		- CHAN, W.; COSTANTINO, N.; LI, R.; LEE, S.C.; SU, Q.; MELVIN, D.; COURT, D.L.; LIU, P., "A recombineering based approach for high-throughput conditional knockout targeting vector construction", NUCLEIC ACIDS RESEARCH, (2007), vol. 35, page E64
		- CHUNG, Y.J.; JONKERS, J.; KITSON, H.; FIEGLER, H.; HUMPHRAY, S.; SCOTT, C.; HUNT, S.; YU, Y.; NISHIJIMA, I.; VELDS, A. ET AL., "A whole-genome mouse BAC microarray with 1-Mb resolution for analysis of DNA copy number changes by array comparative genomic hybridization", GENOME RESEARCH, (2004), vol. 14, pages 188 - 196
		- LIANG, Q.; CONTE, N.; SKARNES, W.C.; BRADLEY, A., "Extensive genomic copy number variation in embryonic stem cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (2008), vol. 105, doi:doi:10.1073/pnas.0805638105, pages 17453 - 17456, XP055303731 DOI: http://dx.doi.org/10.1073/pnas.0805638105
		- ZHENG ET AL., NAR, (1999), vol. 27, no. 11, pages 2354 - 2360
		- SCHLAKE, T.; J. BODE, "Use of mutated FLP-recognition-target-(FRT-)sites for the exchange of expression cassettes at defined chromosomal loci", BIOCHEMISTRY, (1994), vol. 33, doi:doi:10.1021/bi00209a003, pages 12746 - 12751, XP000616165 DOI: http://dx.doi.org/10.1021/bi00209a003
		- WALLACE, H.A.C. ET AL., "Manipulating the mouse genome to engineering precise functional syntenic replacements with human sequence", CELL, (2007), vol. 128, doi:doi:10.1016/j.cell.2006.11.044, pages 197 - 209, XP002481713 DOI: http://dx.doi.org/10.1016/j.cell.2006.11.044
		- PROSSER, H.M. ET AL., "Mosaic complementation demonstrates a regulatory role for myosin Vlla in actin dynamics of Stereocilia", MOL. CELL. BIOL., (2008), vol. 28, pages 1702 - 12
	other	US6596541
	Opposition	WO02066630
		US6596541
		US7294754
		WO2011163314
		EP2480676
		- MURPHY et al., "VelocImmune: Immunoglobulin Variable Region Humanized Mice", MURPHY et al., Melvyn Little, Recombinant Antibodies for Immunotherapy, (20090000), pages 100 - 107, XP055343725 DOI: http://dx.doi.org/10.1017/CBO9780511596773.011
		- STEVENS et al., "VelocImmune - A novel platform", Pharma Focus Asia, (20080000), vol. 8, pages 72 - 74, XP003035947
		- MACDONALD et al., "VELOCIGENE TECHNOLOGY EXTENDED TO HUMANIZATION OF SEVERAL MEGABASES OF COMPLEX GENE LOCI", 1st International MUGEN conference on Animal Models for Human Immunological Disease, Athens, Greece, (20160910), XP055304452
		- MACDONALD et al., "VELOCIGENE TECHNOLOGY EXTENDED TO HUMANIZATION OF SEVERAL MEGABASES OF COMPLEX GENE LOCI", 1st International MUGEN conference on Animal Models for Human Immunological Disease, Athens, Greece, (20060000), XP055343742
		- STEVENS et al., "VelocImmune: Humanization of immunoglobulin loci using VelociGene® technology", 1st International MUGEN conference on Animal Models for Human Immunological Disease, Athens, Greece, (20160910), XP055343747
		- MACDONALD et al., "Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes", PNAS USA, (20140000), vol. 111, no. 14, pages 5147 - 5152, XP055126064 DOI: http://dx.doi.org/10.1073/pnas.1323896111
		- MURPHY et al., "Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice", PNAS USA, (20140000), vol. 111, no. 14, pages 5153 - 5158, XP055162338 DOI: http://dx.doi.org/10.1073/pnas.1324022111
		- "ES cell line", University of California website, URL: http://www.research.uci.edu/facilities-services/tmf/presentations/ Mouse_ES_CellLine.pdf, XP055343751
		- BECK et al., "Genealogies of mouse inbred strains", Nature Genetics, (20070000), vol. 24, no. 1, pages 23 - 25, XP055343752 DOI: http://dx.doi.org/10.1038/71641
		- BECK et al., "Information supplementary to "Genealogies of mouse inbred strains"", Nature Genet, (20000000), vol. 24, no. 1, pages s1 - s4, XP055344285
		- BECK et al., "Supplementary Chart for "Genealogies of mouse inbred strains"", Nature Genet, (20000000), vol. 24, no. 1, page s1, XP055344289
		- SIMPSON et al., "Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice", Nature Genetics, (19970000), vol. 16, no. 1, pages 19 - 27, XP008033035 DOI: http://dx.doi.org/10.1038/ng0597-19
		- CARTER et al., "Standardized Nomenclature for Inbred Strains of Mice", Cancer Research, (19520000), vol. 12, no. 8, pages 602 - 613, XP055344294
		- EPPIG et al., "Guidelines for Nomenclature of Mouse and Rat Strains", Mouse Genome Informatics, (20111000), XP055344298
		- FESTING et al., "Revised nomenclature for strain 129 mice", Mammalian Genome, (19990000), vol. 10, no. 8, page 836, XP055344303 DOI: http://dx.doi.org/10.1007/s003359901099
		- CHIA et al., "The origins and uses of mouse outbred stocks", Nature Genetics, (20050000), vol. 37, no. 11, pages 1181 - 1186, XP055344306 DOI: http://dx.doi.org/10.1038/ng1665
		- RETTER et al., "Sequence and Characterization of the lg Heavy Chain Constant and Partial variable Region of the Mouse Strain 129S1", J. Immunol., (20070000), vol. 179, no. 4, pages 2419 - 2427, XP055268136 DOI: http://dx.doi.org/10.4049/jimmunol.179.4.2419
		- MARTINEZ et al., "The Mouse (Mus musculus) Immunoglobulin Kappa Variable (IGKV) Genes and Joining (IGKJ) Segments", Exp. Clin. Immunogenet ., (19980000), vol. 15, pages 184 - 193, XP055344312 DOI: http://dx.doi.org/10.1159/000019069
		- STEVENS et al., "VelocImmune - A novel platform", Pharma Focus Asia, (20080000), vol. 8, pages 72 - 74
		- MACDONALD et al., "Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes", PNAS USA, (20140000), vol. 111, no. 14, pages 5147 - 5152
		- MURPHY et al., "Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice", PNAS USA, (20140000), vol. 111, no. 14, pages 5153 - 5158
		- "ES cell line", University of California website, URL: http://www.research.uci.edu/facilities-services/tmf/presentations/ Mouse_ES_CellLine.pdf
		- BECK et al., "Genealogies of mouse inbred strains", Nature Genetics, (20070000), vol. 24, no. 1, pages 23 - 25
		- BECK et al., "Information supplementary to "Genealogies of mouse inbred strains"", Nature Genet, (20000000), vol. 24, no. 1, pages s1 - s4
		- BECK et al., "Supplementary Chart for "Genealogies of mouse inbred strains"", Nature Genet, (20000000), vol. 24, no. 1, page s1
		- SIMPSON et al., "Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice", Nature Genetics, (19970000), vol. 16, no. 1, pages 19 - 27
		- CARTER et al., "Standardized Nomenclature for Inbred Strains of Mice", Cancer Research, (19520000), vol. 12, no. 8, pages 602 - 613
		- FESTING et al., "Revised nomenclature for strain 129 mice", Mammalian Genome, (19990000), vol. 10, no. 8, page 836
		- CHIA et al., "The origins and uses of mouse outbred stocks", Nature Genetics, (20050000), vol. 37, no. 11, pages 1181 - 1186
		- RETTER et al., "Sequence and Characterization of the lg Heavy Chain Constant and Partial variable Region of the Mouse Strain 129S1", J. Immunol., (20070000), vol. 179, no. 4, pages 2419 - 2427
		- MARTINEZ et al., "The Mouse (Mus musculus) Immunoglobulin Kappa Variable (IGKV) Genes and Joining (IGKJ) Segments", Exp. Clin. Immunogenet ., (19980000), vol. 15, pages 184 - 193

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p